LY2216684 + quinidine

LY2216684 + quinidine is an investigational combination of two small molecule drugs. LY2216684 (also known as edivoxetine) is a selective norepinephrine reuptake inhibitor developed for the treatment of major depressive disorder and other psychiatric conditions. Quinidine is a class Ia antiarrhythmic agent and antimalarial that also acts as a potent inhibitor of cytochrome P450 2D6 (CYP2D6). In drug combinations, quinidine is often used to increase the bioavailability of co-administered drugs metabolized by CYP2D6 by inhibiting their breakdown. The rationale for combining LY2216684 with quinidine would be to enhance or prolong the pharmacological effect of edivoxetine in individuals who are poor metabolizers via CYP2C19 or have variable CYP2D6 activity, though there are no approved products or clinical evidence supporting this specific combination's use in practice. No unique brand name or marketed product exists for this combination.